Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Fujian Haixi Pharmaceuticals CoHKSE:02637 +8.01%23 Days Inventory is 170.14 as of Dec. 2025, which is 4% below its 10-year median of 177.66. GuruFocus rates HKSE:02637 with a GF Score™ of 23/100. The stock has 2 warning signs investors should review. Among 919 Drug Manufacturers companies, Fujian Haixi Pharmaceuticals Co ranks worse than 52.34% on this metric.
The historical rank and industry rank for Fujian Haixi Pharmaceuticals Co's Days Inventory or its related term are showing as below:
HKSE:02637'
s Days Inventory Range Over the Past 10 Years
Min: 139.46 Med: 177.66 Max: 256.39
Current: 170.14
During the past 4 years, Fujian Haixi Pharmaceuticals Co's highest Days Inventory was 256.39. The lowest was 139.46. And the median was 177.66.
HKSE:02637's Days Inventory is ranked worse than 52.34% of 919
companies
in the Drug Manufacturers industry
Industry Median: 164.87
vs HKSE:02637: 170.14
Inventory Turnover measures how fast the company turns over its inventory within a year.
Fujian Haixi Pharmaceuticals Co's Inventory Turnover for the
six
months ended in Dec. 2025 was 2.15.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Fujian Haixi Pharmaceuticals Co's Inventory-to-Revenue for the
six
months ended in Dec. 2025 was 0.08.
Fujian Haixi Pharmaceuticals Co (HKSE:02637) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Fujian Haixi Pharmaceuticals Co's Inventory Turnover for the
six
months ended in Dec. 2025 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Fujian Haixi Pharmaceuticals Co's Inventory to Revenue for the
six
months ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Fujian Haixi Pharmaceuticals Co Days Inventory Related Terms
Fujian Haixi Pharmaceuticals Co Days Inventory Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fujian Haixi Pharmaceuticals Co Days Inventory Chart
Fujian Haixi Pharmaceuticals Co Annual Data
Trend
Dec22
Dec23
Dec24
Dec25
Days Inventory
256.39
185.17
139.46
170.14
Fujian Haixi Pharmaceuticals Co Semi-Annual Data
Dec22
Dec23
Dec24
Dec25
Days Inventory
256.39
185.17
139.46
170.14
HKSE:02637 vs ZTS: Days Inventory Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Fujian Haixi Pharmaceuticals Co's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fujian Haixi Pharmaceuticals Co Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Fujian Haixi Pharmaceuticals Co's Days Inventory distribution charts can be found below:
* The bar in red indicates where Fujian Haixi Pharmaceuticals Co's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fujian Haixi Pharmaceuticals Co (HKSE:02637) has a Days Inventory of 170.14 as of Dec. 2025. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Fujian Haixi Pharmaceuticals Co and its competitors. This is near median its historical median of 177.66. Over the past decade, Fujian Haixi Pharmaceuticals Co's Days Inventory has ranged from 139.46 to 256.39. According to the industry distribution chart, Fujian Haixi Pharmaceuticals Co ranks #481 out of 919 companies in the Drug Manufacturers industry, placing it in the top 52.3%.
Is Fujian Haixi Pharmaceuticals Co's Days Inventory too high?
Fujian Haixi Pharmaceuticals Co's current Days Inventory of 170.14 is near median its 10-year median of 177.66. Over the past 10 years, this metric has ranged from a low of 139.46 to a high of 256.39. The Drug Manufacturers industry median Days Inventory is 164.87. Fujian Haixi Pharmaceuticals Co's value of 170.14 is 3.2% above this industry median. Based on the distribution chart, Fujian Haixi Pharmaceuticals Co ranks #481 out of 919 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Fujian Haixi Pharmaceuticals Co has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Fujian Haixi Pharmaceuticals Co's Days Inventory compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Fujian Haixi Pharmaceuticals Co ranks #481 out of 919 companies for Days Inventory. This places Fujian Haixi Pharmaceuticals Co in the lower half of its industry. The industry median Days Inventory is 164.87. Fujian Haixi Pharmaceuticals Co's value of 170.14 is 3.2% above this benchmark. Historically, Fujian Haixi Pharmaceuticals Co's own Days Inventory has ranged from 139.46 to 256.39 over the past decade. While the company's 10-year median is 177.66 vs. the industry median of 164.87, Fujian Haixi Pharmaceuticals Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 164.87, based on 919 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fujian Haixi Pharmaceuticals Co's current Days Inventory of 170.14 is 3.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Fujian Haixi Pharmaceuticals Co and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 164.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fujian Haixi Pharmaceuticals Co's current Days Inventory is 170.14, which is near median its own 10-year median of 177.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fujian Haixi Pharmaceuticals Co stock overvalued right now?
Fujian Haixi Pharmaceuticals Co (HKSE:02637) has a current Days Inventory of 170.14. The current Days Inventory is 170.14, which is near median its 10-year median of 177.66 and 3.2% above the Drug Manufacturers industry median of 164.87. Fujian Haixi Pharmaceuticals Co's overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Fujian Haixi Pharmaceuticals Co (HKSE:02637), the current Days Inventory is 170.14 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Fujian Haixi Pharmaceuticals Co Ltd is a commercial-stage pharmaceutical company that integrates R&D, production and sales capacities, with a pipeline of inventive drug candidates. It has a diversified product portfolio and pipeline in the fastest growing therapeutic areas in China. The company's commercialized product portfolio consisted of generic drugs for digestive system diseases, cardiovascular system diseases, endocrine system diseases, nervous system diseases and inflammatory diseases. Its inventive drug pipeline focuses on drug candidates in a variety of indications, including one potential first-in-class oncology drug candidate, one potential first oral drug therapy for wet age-related macular degeneration /diabetic macular edema /retinal vein occlusion.
23GF Score
Get the complete analysis for HKSE:02637
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02637 has been successfully added to your 
